Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0152030 (
skin irritation
)
2,146
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of 4% chlorhexidine detergent and 2% triclosan detergent on the resident flora of the hands was compared on 20 healthy volunteers. The initial and prolonged effects of the agents were assessed by a modification of the Peterson glove rinse test after multiple hand washes.
Chlorhexidine
detergent was significantly more effective than triclosan detergent (p less than 0.001) which in turn was more effective than non-medicated soap (p less than 0.001) for both initial and prolonged effect.
Chlorhexidine
, but not triclosan, showed a significantly greater prolonged effect than initial effect (p less than 0.01). Five volunteers (25%) experienced
skin irritation
with triclosan; no side effects were experienced with chlorhexidine.
...
PMID:Surgical hand disinfection: comparison of 4% chlorhexidine detergent solution and 2% triclosan detergent solution. 196 36
Chlorhexidine
(CLX) is the most widely used antiseptic for wound and skin disinfection. Despite its potent bactericidal action,
skin irritation
is observed when it is used topically. This study aimed to evaluate the mechanisms underlying CLX-induced toxicity on human dermal fibroblasts with special emphasis on factors that may mediate or counteract its undesirable effects. Cells were exposed to CLX concentrations of 0.00005-0.025% for 3, 6, 8 or 24 h in the absence or presence of different concentrations of foetal calf serum (FCS) (2, 5 and 10%). Depletion of cell ATP occurred, in a time- and concentration-dependent manner, in all experimental conditions at [CLX] >0.001%. At 24 h of CLX exposure time, the decrease in intracellular ATP was produced from a 10-times lower CLX concentration (0.0001%). Concentrations > or =0.02% produced total loss of ATP. However, cell survival was maintained after CLX treatment for 3 and 8 h and CLX concentrations > or =0.005% were required to produce total cell death. CLX exerted an inhibitory concentration-dependent effect on DNA synthesis from concentrations as low as 0.0001%. Only FCS at 10% appeared to have a cytoprotective action against CLX-induced cytotoxicity.
...
PMID:Mechanisms underlying chlorhexidine-induced cytotoxicity. 1156 48
Despite the progress in curative and preventive medicine, skin lesions after injuries or surgical interventions are still a big problem. The aim of wound care is to get damaged tissues to heal as soon as possible. A gel-forming material helps to maintain proper humidity in the wound and promotes the healing process. For this purpose, a healing gel containing the active substance chlorhexidine based on poloxamer was prepared. The aim of this study was to assess in vivo the therapeutic efficacy of chlorhexidine-poloxamer gel in treatment of wounds caused experimentally and inoculated with bacteria, and the effect of an antiseptic gel applied on a healthy rat skin. Wistar albino rats were selected for these studies. The effect of an antiseptic gel on the healing excision and incision wounds, as well as the irritating effect on the healthy skin were assessed. Cross-sectional full-thickness specimens from each group were collected at the end of the experiment to assess the histopathological alterations.
Chlorhexidine
-poloxamer gels accelerate the healing of infected skin wounds because the active ingredient chlorhexidine remains at the application site, and systemic effects are avoided. Moreover, chlorhexidine-poloxamer gels are easy to use because they can be easily washed off from the wound surface by water. The present study has revealed that chlorhexidine-poloxamer gels promote healing of full-thickness skin wounds without
skin irritation
. This makes it possible to plan further clinical trials in the target species.
...
PMID:Therapeutic activity of chlorhexidine-poloxamer antiseptic gel on wound healing in rats: a preclinical study. 2962 19